Satoshi Ueshima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Satoshi Ueshima has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Daiki Hira
Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan
2 shared publications - Toshiya Katsura
College of Pharmaceutical Sciences, Ritsumeikan University, Noji-higashi, Kusatsu-shi, Shiga, Japan
2 shared publications - Chieri Fujino
College of Pharmaceutical Sciences, Ritsumeikan University, Noji-higashi, Kusatsu-shi, Shiga, Japan; Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan
1 shared publication Chiho Tomitsuka
Laboratory of Clinical Pharmaceutics and Therapeutics, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu
1 shared publicationDaiki Hira
Laboratory of Clinical Pharmacy, College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Japan
1 shared publication- Hideki Itoh
Division of Patient Safety, Hiroshima University Hospital, Japan (H.I.).
1 shared publication
Latest Publications
- Open Access
- 24 October 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (12) , 100190
Downregulation of hepatic sulfotransferase 1E1 expression associated with decreased expression of multidrug resistance–associated protein 2
- 24 October 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (12) , 100190
Open AccessDownregulation of hepatic sulfotransferase 1E1 expression associated with decreased expression of multidrug resistance–associated protein 2
- Open Access
- 10 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Pharmacokinetic and pharmacodynamic characterization of remimazolam in older Japanese adults who underwent general anesthesia at early stage of infusion
The pharmacokinetic and pharmacodynamic characteristics of remimazolam (RMZ), a novel ultrashort-acting anesthetic, administration alone in clinical practice remain poorly understood. Therefore, we aimed to evaluate the relationship between patient characteristics and the pharmacokinetics and pharmacodynamics of RMZ in older Japanese adults who underwent general anesthesia at the early stage of infusion. Plasma samples were collected from 20 patients (median age: 71.7 years; range: 42.2–88.6 years) who were intravenously administered RMZ without other anesthetics such as remifentanil or fentanyl. The pharmacokinetic profiles of RMZ and its metabolite (CNS7054) were described using three- and two-compartment models with a transit compartment, respectively. The bispectral index was selected as a clinical measure of sedation. The pharmacokinetic-pharmacodynamic profile of RMZ was described using a maximum inhibitory model with an effect compartment. The population pharmacokinetic and pharmacodynamic parameters of RMZ were obtained using the nonlinear mixed-effects modeling program. RMZ clearance (CL) was increased nonlinearly with increasing body weight (BW), and the population mean CL for a typical patient (BW, 60.4 kg) was 1.38 L/min. No patient characteristics affected CNS7054 pharmacokinetics. The population mean of the half-maximal inhibitory RMZ concentration decreased nonlinearly with increasing age or BW. However, these characteristics did not meet the criteria for pharmacokinetic and pharmacodynamic covariates. Our results suggest that BW is an intrinsic factor affecting RMZ pharmacokinetics in Japanese patients under general anesthesia in the early stages of infusion; however, no patient characteristics affected RMZ pharmacodynamics.
- 10 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessPharmacokinetic and pharmacodynamic characterization of remimazolam in older Japanese adults who underwent general anesthesia at early stage of infusion
The pharmacokinetic and pharmacodynamic characteristics of remimazolam (RMZ), a novel ultrashort-acting anesthetic, administration alone in clinical practice remain poorly understood. Therefore, we aimed to evaluate the relationship between patient characteristics and the pharmacokinetics and pharmacodynamics of RMZ in older Japanese adults who underwent general anesthesia at the early stage of infusion. Plasma samples were collected from 20 patients (median age: 71.7 years; range: 42.2–88.6 years) who were intravenously administered RMZ without other anesthetics such as remifentanil or fentanyl. The pharmacokinetic profiles of RMZ and its metabolite (CNS7054) were described using three- and two-compartment models with a transit compartment, respectively. The bispectral index was selected as a clinical measure of sedation. The pharmacokinetic-pharmacodynamic profile of RMZ was described using a maximum inhibitory model with an effect compartment. The population pharmacokinetic and pharmacodynamic parameters of RMZ were obtained using the nonlinear mixed-effects modeling program. RMZ clearance (CL) was increased nonlinearly with increasing body weight (BW), and the population mean CL for a typical patient (BW, 60.4 kg) was 1.38 L/min. No patient characteristics affected CNS7054 pharmacokinetics. The population mean of the half-maximal inhibitory RMZ concentration decreased nonlinearly with increasing age or BW. However, these characteristics did not meet the criteria for pharmacokinetic and pharmacodynamic covariates. Our results suggest that BW is an intrinsic factor affecting RMZ pharmacokinetics in Japanese patients under general anesthesia in the early stages of infusion; however, no patient characteristics affected RMZ pharmacodynamics.
- 1 September 2017
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 27 (9) , 329-336
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation
During anticoagulant therapy, major bleeding is one of the most severe adverse effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concentrations of apixaban, a direct inhibitor of coagulation factor X. A total of 70 plasma concentrations of apixaban from 44 Japanese patients with atrial fibrillation were analyzed. In these analyses, the plasma trough concentration/dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) polymorphisms. Influences of various clinical laboratory parameters (age, serum creatinine, estimated glomerular filtration rate, aspartate amino transferase, and alanine amino transferase) on the plasma trough C/D ratio of apixaban were included in analyses. Although no ABCB1 polymorphisms affected the plasma trough C/D ratio of apixaban, the plasma trough C/D ratio of apixaban was significantly higher in patients with the ABCG2 421A/A genotype than in patients with the ABCG2 421C/C genotype (P<0.01). The plasma trough C/D ratio of apixaban in patients with CYP3A5*1/*3 or *3/*3 genotypes was also significantly higher than that in patients with the CYP3A5*1/*1 genotype (P<0.05). Furthermore, the plasma trough C/D ratio of apixaban decreased with increased estimated glomerular filtration rate. These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concentrations of apixaban.
- 1 September 2017
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 27 (9) , 329-336
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation
During anticoagulant therapy, major bleeding is one of the most severe adverse effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concentrations of apixaban, a direct inhibitor of coagulation factor X. A total of 70 plasma concentrations of apixaban from 44 Japanese patients with atrial fibrillation were analyzed. In these analyses, the plasma trough concentration/dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) polymorphisms. Influences of various clinical laboratory parameters (age, serum creatinine, estimated glomerular filtration rate, aspartate amino transferase, and alanine amino transferase) on the plasma trough C/D ratio of apixaban were included in analyses. Although no ABCB1 polymorphisms affected the plasma trough C/D ratio of apixaban, the plasma trough C/D ratio of apixaban was significantly higher in patients with the ABCG2 421A/A genotype than in patients with the ABCG2 421C/C genotype (P<0.01). The plasma trough C/D ratio of apixaban in patients with CYP3A5*1/*3 or *3/*3 genotypes was also significantly higher than that in patients with the CYP3A5*1/*1 genotype (P<0.05). Furthermore, the plasma trough C/D ratio of apixaban decreased with increased estimated glomerular filtration rate. These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concentrations of apixaban.